Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G5SU
|
|||
| Former ID |
DIB001155
|
|||
| Drug Name |
Paquinimod
|
|||
| Synonyms |
ABR-215757; ABR-25757; Project 57-57, Active Biotech
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lupus [ICD-11: 4A40; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Active Biotech AB
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N2O3
|
|||
| Canonical SMILES |
CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C
|
|||
| InChI |
1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
|
|||
| InChIKey |
DIKSYHCCYVYKRO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 248282-01-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calgranulin B (S100A9) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | Endogenous TLR signaling | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| IL1 and megakaryotyces in obesity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01487551) An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod). U.S. National Institutes of Health. | |||
| REF 2 | Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.